PCOS After Stopping Birth Control: What to Do, and When

PCOS after stopping birth control: which tests are valid, why irregular cycles skip the 12-month wait, what treatment works, and what it costs in the U.S.

Key takeaways

• The pill masked a pattern that already existed. It did not create the condition.
• Which test means anything depends on how long you have been off hormonal contraception.
• Irregular cycles and cycles longer than 35 days are a reason to start evaluation without delay, per ASRM’s 2026 committee opinion.
• Letrozole is first-line for ovulation induction and is used off-label in the U.S. Dose escalation, or a longer course, is a common next step when the first cycle does not produce ovulation.
• Whether a state fertility law applies to you depends on your plan type, not your address.
• Most of this article describes average effects in populations. Your case can differ, and nothing here replaces an exam and a clinician’s plan.

Maya is 30 and five months off the pill. She has had two periods since, both after cycles longer than 40 days, and the acne along her jaw is back for the first time since she was 17. Her clinician told her to try for a year.

Stopping hormonal birth control does not cause PCOS, now renamed polyendocrine metabolic ovarian syndrome (PMOS). It can reveal a pattern that was already there. Most people who stop the pill conceive within a year, but that average comes from people who ovulate. If your cycles are long or irregular, U.S. fertility guidance says evaluation should start now, not after 12 months, and androgen blood tests are only interpretable at least three months off the pill.

Can stopping the pill cause PCOS?

No. Stopping hormonal contraception does not cause PCOS or PMOS. What it can do is remove the masking effect, so a pattern that was always there becomes visible.

The condition was renamed PMOS on May 12, 2026, after a 14-year consensus process involving 56 organizations and more than 14,000 survey responses (The Lancet, 2026; Endocrine Society, 2026). A three-year transition is underway. The International Guideline is expected to adopt the new name in its 2028 update, and ICD coding will follow. Both terms describe one condition, so expect PCOS on lab forms and PMOS in newer articles.

Prevalence estimates depend on which diagnostic criteria a study used, which is why the numbers disagree. The U.S. Office on Women’s Health says 1 in 10 women of childbearing age, or 5% to 10% (HHS OWH, 2025). ACOG says up to 13 in 100 U.S. women of reproductive age (ACOG). The 2026 consensus paper uses 1 in 8 globally. All three are defensible; none is a headcount.

Diagnosis is often slow. In a U.S. survey cohort of 1,056 women with confirmed PCOS, the average gap from first symptoms to diagnosis was 5 years, 69.2% waited a year or more, and 72.9% saw more than one provider (JCEM, 2025). Those respondents were volunteers recruited through PCOS communities, and 78.9% had private insurance, so the sample skews insured and already engaged in care. The delay is real; the exact size in the whole U.S. population is not known.

Why the pill hid it

Combined hormonal contraception suppresses ovulation and raises sex hormone-binding globulin (SHBG), a protein that binds testosterone and lowers the free fraction. The result is a regular withdrawal bleed that looks like a cycle, and androgen levels that can look normal.

That is why a “normal” testosterone result in month one or two tells you very little. The 2023 International Evidence-Based Guideline states that biochemical hyperandrogenism is very difficult to assess reliably on the combined pill, and that if the measurement is truly needed, the pill should be withdrawn for at least three months with other contraception used in the interim (Teede et al., JCEM, 2023).

Antral follicle counts and anti-Müllerian hormone (AMH) can also shift with current or recent pill use, the same guideline notes. AMH is accepted as an alternative to ultrasound for defining polycystic ovarian morphology in adults, but not as a standalone diagnostic test (2023 Guideline summary).

A high AMH is not reassurance that you are fertile. It describes how many small follicles are present, not whether one is releasing an egg.

When to test hormones after stopping the pill

Some tests are meaningful today. Others need three months off the pill. Sorting them is the single most useful thing you can do in your first month, because it prevents both wasted testing and a falsely reassuring result.

The diagnostic pathway matters here too. In adults, PCOS/PMOS is diagnosed when two of three features are present: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. If you have irregular cycles and visible signs of androgen excess, neither an ultrasound nor an AMH is required (JCEM, 2023; AAFP, 2026). Clinical signs are assessed by examination, not by a lab.

The test-validity calendar

Two practical notes. First, “post-pill PCOS” is not a recognized diagnosis. Medical organizations do not list it as a condition, and symptoms after stopping are usually either unmasked PCOS/PMOS or a temporary adjustment as ovulation resumes (Medical News Today, 2026). Second, if bleeding has not returned within 90 days after stopping, and your cycles were regular before, that alone is a reason to book an appointment. If your cycles were already irregular before the pill, the threshold most clinicians use is six months (AAFP, 2026).

Do you have to wait a year before seeing a fertility specialist?

No, if your cycles are irregular. The 12-month rule was written for regular, unprotected intercourse without a known cause.

ASRM’s 2026 committee opinion says diagnostic testing “should be initiated without delay on presentation with a condition known to cause infertility.” Its list of such conditions opens with irregular menstrual cycles, cycle length under 25 or over 35 days, intermenstrual bleeding, and amenorrhea (ASRM, 2026).

The 12-month and 6-month thresholds still apply to people with regular cycles: 12 months under age 35, and 6 months at 35 or older. Above 40, immediate evaluation and treatment may be warranted.

Why the distinction matters: a rule designed to avoid over-testing people who are probably ovulating can turn a treatable condition into a year of waiting through cycles that have little chance of producing a pregnancy.

One real-world caveat. ASRM’s opinion guides clinicians; it does not bind insurers. Some plans still apply their own 12-month infertility definition to prior authorization. If you are denied, ask for the plan’s clinical policy on infertility diagnosis and have your clinician document the irregular cycles in the referral.

A sentence that helps at the visit: “My cycles are longer than 35 days and irregular, so I understand evaluation isn’t supposed to wait 12 months. Can we start the workup now?”

The treatment ladder, with real numbers

Ovulation induction comes first for most people with PCOS/PMOS who are not ovulating. Letrozole is the recommended first-line drug in both U.S. and international guidance (ACOG Practice Bulletin 194, reaffirmed 2025; 2023 International Guideline). It is off-label for this use in the United States.

The most-cited trial randomized 750 anovulatory women with PCOS, mostly in the U.S., to letrozole or clomiphene for up to five cycles. Cumulative live birth was 27.5% with letrozole and 19.1% with clomiphene, and ovulation occurred in 61.7% of letrozole cycles versus 48.3% of clomiphene cycles (Legro et al., NEJM, 2014).

Read those numbers honestly. 27.5% is a real chance over five cycles, and most people who stop after two cycles never reach it. It is also not a guarantee. And a cycle that does not produce ovulation at 2.5 mg usually means the dose was too low, not that the drug failed.

Dose escalation is standard: 2.5 mg daily for five days, then 5 mg, then 7.5 mg in later cycles if ovulation does not occur. A 2024 retrospective series of 189 cycles in 52 patients found cumulative ovulation above 84% across regimens once doses were stepped up, and found that starting at 5 mg or using a 10-day course produced ovulation sooner than 2.5 mg for five days (F&S Reports, 2024). It was a single-center chart review with provider-chosen regimens, so treat the timing finding as a reasonable hypothesis, not a rule.

Comparing the options

Cost figures are illustrative anchors from one U.S. fertility clinic’s published 2026 self-pay price list (Illume Fertility, 2026). They are not a national average, and pharmacy discount pricing for the oral drugs varies widely.

On the freeze-all row: a 2025 Cochrane review found probably little or no difference in cumulative live birth between freeze-all and conventional IVF, so the case for freeze-all in PCOS rests mainly on lowering ovarian hyperstimulation syndrome (OHSS), a rare but serious complication. The same review found a possible increase in hypertensive disorders of pregnancy with freeze-all, on low-quality evidence (Cochrane, 2025).

What it costs, and whether insurance covers it

Medication is usually cheap. Monitoring, procedures and embryos are not. Knowing which line of the bill you are on lets you plan the year instead of discovering it cycle by cycle.

The bigger question is whether your state’s fertility law applies to you. As of November 2025, KFF counted 23 states with some requirement that private insurers cover infertility services, and 18 states with some infertility coverage through Medicaid (KFF, 2025). RESOLVE, which counts differently, lists 15 states plus D.C. with a specific IVF coverage requirement (RESOLVE, 2026). Verify with your own plan document, not a map.

Most people who work for a large employer are in a self-insured plan, and those plans generally fall outside state insurance mandates. KFF reports about six in ten covered workers are in self-funded plans. Coverage then depends on what your employer chose to buy.

California’s SB 729 is a useful example of the boundary. It requires fully insured large-group plans (employers with 100 or more workers) to cover infertility diagnosis and treatment, including IVF, starting January 1, 2026, a date pushed back from July 2025 by follow-up legislation. It does not reach self-insured employers, small-group plans, or Medi-Cal (CalMatters, 2025).

Three questions for your insurer, in this order

1. “Is this plan self-insured or fully insured?”
2. “What does the plan document say about infertility diagnosis versus treatment?”
3. “Is ovulation induction covered, and is ultrasound monitoring covered separately?”

Ask before the first cycle. A denied claim after a monitored cycle is a budgeting problem you can prevent.

While you wait: what helps and what wastes money

Three things are worth doing before any appointment. Most of the rest can wait, and some of it costs money without changing a decision.

Do these now

• Start folic acid, 400 to 800 mcg daily. The U.S. Preventive Services Task Force gives this a Grade A recommendation for anyone who could become pregnant, starting at least a month before conception (USPSTF, 2023).
• Track cycle start dates, not symptoms. Note the first day of every bleed and the interval between them.
• Ask whether a semen analysis is planned. Male factors contribute in up to 40% of cases, and testing both partners at once saves months (ASRM, 2026).

Treat as optional

• Myo-inositol. It is widely sold and generally well tolerated. A systematic review commissioned for the 2023 guideline found the evidence “limited and inconclusive” and found metformin superior on some clinical measures (JCEM, 2024). It is not a substitute for ovulation induction.
• Ovulation predictor strips. ASRM notes that people with PCOS/PMOS may have a tonic elevation in basal LH, which can produce false-positive results on urinary LH tests (ASRM, 2026). Use them as one signal among several, not as proof.

Skip

Detoxes, seed cycling and “hormone balancing” programs have no clinical support. So does paying for an AMH test to answer “can I still get pregnant.” AMH does not measure that.

If you carry extra weight and want to act on it, treat weight change as one lever among several, not an entry requirement. A 2026 post hoc analysis of the 75 women in the UK BAMBINI trial (PCOS, BMI 35 or higher, randomized to bariatric surgery or medical care) found ovulation returned in 19% of participants who lost no weight versus more than 50% of those who lost weight (Human Reproduction, 2026). That is a secondary analysis of a surgery trial, with groups of roughly a dozen people each. It shows an association in a specific population. It does not prove that losing 10 pounds will restart your cycles. The 2023 guideline recommends a 5% to 10% loss where weight is elevated, and also warns clinicians about weight stigma.

When to stop waiting

Some situations have fixed timelines. The rest are judgment calls you should make with a clinician, but knowing the thresholds prevents drift.

Escalation table

Same-day or emergency care: a positive pregnancy test with pain or bleeding; severe abdominal or shoulder pain; fainting or dizziness. These can signal an ectopic pregnancy. Also seek urgent care for OHSS symptoms during any ovulation-induction cycle: rapid weight gain, severe bloating, shortness of breath, or much less urine than usual.

Within days: very heavy bleeding, bleeding between periods, rapid facial hair growth or voice change, milky nipple discharge, or new severe headaches with visual changes.

Endometrial protection is the step people skip

When ovulation stops, the uterine lining keeps building under estrogen with nothing to shed it. The Royal College of Obstetricians and Gynaecologists advises inducing a withdrawal bleed at least every three to four months, and cites moderate-quality data for a 2.9-fold higher endometrial cancer risk in PCOS (95% CI 1.52–5.48) (RCOG Green-top Guideline 33). That guideline is British and dates from 2014, so treat it as a benchmark rather than a U.S. rule.

The absolute risk is low. The 2023 International Guideline tells clinicians that the overall chance of endometrial cancer is low and does not recommend routine screening, while advising that long-standing untreated amenorrhea, higher weight and type 2 diabetes add risk (2023 Guideline recommendations). Options include cyclical progestin, a combined pill, or a progestin-releasing IUD. Metformin does not substitute for this protection.

Pregnancy risks worth planning for, without alarm

Pregnancies in people with PCOS/PMOS carry higher odds of several complications, and most still end with a healthy mother and baby. A 2024 systematic review of 104 studies and 106,690 pregnancies found higher odds of gestational diabetes (OR 2.41, 95% CI 1.95–2.99), preeclampsia (OR 2.30, 95% CI 1.88–2.82) and miscarriage (OR 1.49, 95% CI 1.20–1.85) than in women without PCOS (Nature Communications, 2024).

That review informed the 2023 guideline. It included mostly observational studies, and the odds stayed elevated when age and BMI were matched. Other large cohorts that adjust for more factors report smaller increases, so the true excess is probably somewhere between modest and twofold depending on the outcome.

Two things follow. Tell your obstetric clinician about the diagnosis at the first visit, and expect an early glucose test. Those are population odds, not a prediction about you.

Two more items belong in preconception planning. Anti-androgen drugs such as spironolactone are not for use during pregnancy and require reliable contraception until you stop them. GLP-1 medications should be stopped before conception: the FDA labels for semaglutide products direct patients to discontinue at least two months before a planned pregnancy because of the long half-life (Wegovy prescribing information, 2025).

GLP-1 drugs are promising in PCOS/PMOS and unproven for fertility. A 2026 scoping review found weight loss of roughly 7.6 to 11.5 kg and improved cycle regularity, but no included study confirmed ovulation with progesterone testing or measured live birth (Biomedicines, 2026). Weight loss is also not recommended during pregnancy.

Two conditions that get missed

Obstructive sleep apnea is far more common in PCOS/PMOS. A 2025 meta-analysis of eight cross-sectional studies (942 participants) found pooled prevalence of 37% versus 6% without the condition, with an odds ratio of 9.52 (Frontiers in Endocrinology, 2025). The heterogeneity was very high and the studies used different screening methods, so the exact share is uncertain. If you snore, wake unrefreshed, or fall asleep during the day, ask for a sleep evaluation.

Depression and anxiety are also more common. A 2024 overview of ten systematic reviews found pooled prevalence of depressive disorders at 34.8% and anxiety disorders at 16.9%, although estimates shifted a lot depending on which questionnaire a study used (Archives of Women’s Mental Health, 2024). Both are treatable, and neither is a personal failing. Ask for screening rather than waiting to be asked.

What realistic progress looks like

Progress here is unglamorous. It looks like a diagnosis you can act on, a cycle you can date, a next step with a price attached, and a decision date on the calendar.

Expect the first three months to be mostly information-gathering. Expect at least one test to be unhelpful because it was drawn too early. Expect that stopping treatment after two cycles means you saw part of the trial protocol rather than all of it; some of the benefit accrues early, but the cumulative figures come from people who completed five.

If the letrozole path works, you may ovulate on the first dose or need one or two escalations. If it does not, you will have a documented reason to move to a specialist, which is faster than arriving without one.

Your first four weeks

Today

• Take a pregnancy test if there is any chance you are pregnant.
• Start folic acid, 400 to 800 mcg.
• Write down the date of your last spontaneous period and the last day of your last pill pack.

This week

• Book an appointment and say the words “irregular cycles” when you request it.
• Ask your insurer whether the plan is self-insured or fully insured.

Weeks 2 to 4

• Request: pregnancy test, TSH, prolactin, estradiol, FSH, LH, and a clinical androgen assessment.
• If your cycles are irregular and you have visible androgen signs, ask whether a diagnosis can be made without ultrasound or AMH.
• Schedule androgen labs for at least three months after your last pill, if they are needed.
• Ask whether a semen analysis is planned for your partner.

Reassessment point

• At 90 days without a bleed, or after three letrozole cycles, sit down with your notes and apply the escalation table.

Clinic script

“I stopped the pill in [month]. My cycles are [length] and irregular, and I have [acne, facial hair, scalp hair loss]. I understand that irregular cycles are a reason to evaluate without waiting 12 months. I would like to confirm the diagnosis, protect my endometrium if I am not bleeding regularly, and start ovulation induction if I am anovulatory. What is the plan, and when do we reassess?”

What has changed recently

• May 2026: PCOS renamed PMOS after a global consensus. Diagnosis and treatment did not change; the label did.
• 2026: ASRM’s fertility evaluation opinion replaced its 2021 version and explicitly lists irregular cycles as a reason to start testing without delay.
• 2025: A Cochrane review found little or no difference in cumulative live birth between freeze-all and conventional IVF, sharpening the freeze-all case around OHSS prevention rather than success rates.

Limitations of this guide

This article summarizes population-level evidence for a U.S. reader. It cannot tell you whether you ovulate, what your testosterone means, or which treatment your insurer will pay for. Several of the strongest numbers here come from one trial or one cohort, and many come from observational data where causation cannot be established. Guidance from ASRM and ACOG is written for clinicians and is not a coverage guarantee. If your symptoms are severe, rapidly worsening, or include the red flags above, act on those before anything in this article.

FAQ

Can I get pregnant with PCOS if my periods are irregular?
Yes, usually with help. Irregular periods often mean ovulation is not happening reliably, and pregnancy requires ovulation. In the largest U.S. trial, letrozole produced ovulation in 61.7% of cycles, and 27.5% of participants had a live birth within five cycles. The barrier is timing, diagnosis and treatment access, not fertility potential.

Is “post-pill PCOS” a real diagnosis?
No. Medical organizations do not recognize post-pill PCOS as a distinct condition, and it does not appear in the 2023 International Guideline or in ACOG’s practice bulletin. Symptoms that appear after stopping the pill are usually either PCOS/PMOS the pill was masking or a temporary adjustment as ovulation resumes. The distinction matters, because only one of them needs long-term management.

How long after stopping the pill should I test my hormones?
Total and free testosterone should be measured at least three months after your last combined pill. Estrogen in the pill raises SHBG and alters androgen production, so results before that window are hard to interpret. Thyroid-stimulating hormone, prolactin and a clinical androgen exam can be done immediately. AMH can be drawn sooner, but recent pill use may lower it.

Should I wait 12 months before seeing a specialist?
Not if your cycles are irregular. ASRM’s 2026 opinion says testing should begin without delay when a condition known to cause infertility is present, and lists irregular cycles, cycle length over 35 days, and amenorrhea among those conditions. The 12-month threshold applies to regular cycles without a known cause. Your insurer may still apply its own rule.

Is letrozole safe for a baby conceived on it?
Pooled data on 4,697 letrozole-conceived pregnancies found a congenital malformation rate of 2.15%, comparable to background rates and not significantly different from clomiphene (Human Reproduction Update, 2021). That review rated the certainty low to moderate. A 2025 meta-analysis of 20 trials found no clear increase but rated certainty very low. Reassuring, not settled.

Why did my period come back and then stop again?
Early cycles after stopping the pill are often anovulatory. A bleed can happen without ovulation, then be followed by a long gap while the system tries again. If cycles were regular before the pill, 90 days without bleeding warrants evaluation; if they were already irregular, the usual threshold is six months. Do not assume the first period means the system has reset.

Do I need IVF with PCOS?
Most people do not start there. Oral ovulation induction is first-line, and IVF is usually reserved for resistance to induction, tubal or semen factors, or age-related urgency. IVF outcomes in PCOS are good, with live birth after first transfer around 49% in one trial, but the cost rises by an order of magnitude and the monitoring burden is higher.

Will metformin help me get pregnant?
It can help modestly and is best used alongside ovulation induction rather than alone. A Cochrane review found improved live birth versus placebo (OR 1.59, 95% CI 1.00–2.51) on low-quality evidence from four small trials. In a three-arm U.S. trial, live birth was 7.2% with metformin alone versus 22.5% with clomiphene. It is not a first-line fertility drug.

Sources

1. Teede HJ, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. JCEM. 2023. https://academic.oup.com/jcem/article/108/10/2447/7242360
2. Monash University. 2023 International Guideline Summary. https://www.monash.edu/__data/assets/pdf_file/0003/3371133/PCOS-Guideline-Summary-2023.pdf
3. ASRM. Fertility evaluation of infertile women: a committee opinion. 2026. http://www.asrm.org/practice-guidance/practice-committee-documents/fertility-evaluation-of-infertile-women-a-committee-opinion-2026/
4. ACOG. Polycystic Ovary Syndrome, Practice Bulletin 194 (June 2018, reaffirmed 2025). https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/06/polycystic-ovary-syndrome
5. Legro RS, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. NEJM. 2014. https://doi.org/10.1056/NEJMoa1313517
6. Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. The Lancet. 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
7. Endocrine Society. PMOS: new name announcement. 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
8. HHS Office on Women’s Health. Polycystic ovary syndrome. 2025. https://womenshealth.gov/a-z-topics/polycystic-ovary-syndrome
9. JCEM. Determinants of Health Care Dissatisfaction Among a US Population-Based Cohort of Women With PCOS. 2025. https://academic.oup.com/jcem/article/110/3/838/7731871
10. Klein DA, et al. Amenorrhea: A Practical Approach to Diagnosis and Management. AAFP. 2026. https://www.aafp.org/afp/2026/0700/amenorrhea
11. F&S Reports. A comparison of letrozole regimens for ovulation induction in women with PCOS. 2024. https://www.fertstertreports.org/article/S2666-3341(24)00045-X/fulltext
12. Sharpe A, et al. Metformin for ovulation induction (excluding gonadotrophins) in women with PCOS. Cochrane. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6915832/
13. Cochrane. Fresh versus frozen embryo transfers for assisted reproduction. 2025. https://www.cochrane.org/evidence/CD011184_fresh-versus-frozen-embryo-transfers-assisted-reproduction
14. KFF. Mandated Coverage of Infertility Treatment. 2025. https://www.kff.org/state-health-policy-data/state-indicator/infertility-coverage/
15. RESOLVE. Insurance Coverage by State. 2026. https://resolve.org/learn/financial-resources/insurance-coverage/insurance-coverage-by-state/
16. CalMatters. California insurers must cover IVF under new law. 2025. https://calmatters.org/health/2025/12/ivf-fertility-mandate-new-law/
17. USPSTF. Folic Acid Supplementation to Prevent Neural Tube Defects. 2023. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
18. Fitz V, et al. Inositol for PCOS: systematic review and meta-analysis. JCEM. 2024. https://academic.oup.com/jcem/article/109/6/1630/7504796
19. Human Reproduction. Ovulatory recovery following weight loss in women with PCOS: post hoc analysis of BAMBINI. 2026. https://doi.org/10.1093/humrep/deag037
20. RCOG. Long-term Consequences of Polycystic Ovary Syndrome, Green-top Guideline 33. 2014. https://www.rcog.org.uk/media/qmtlp2b0/gtg_33.pdf
21. Nature Communications. Systematic review and meta-analysis of pregnancy outcomes in women with PCOS. 2024. https://www.nature.com/articles/s41467-024-49749-1
22. Pundir J, et al. Risk of foetal harm with letrozole use in fertility treatment. Human Reproduction Update. 2021. https://academic.oup.com/humupd/article/27/3/474/6055043
23. Human Reproduction. Letrozole and foetal malformations: meta-analysis of RCTs. 2025. https://pubmed.ncbi.nlm.nih.gov/40532516
24. FDA. Wegovy (semaglutide) prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
25. Biomedicines. Semaglutide in PCOS: a scoping review. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13510204/
26. Frontiers in Endocrinology. Obstructive sleep apnea syndrome in PCOS: systematic review and meta-analysis. 2025. https://pubmed.ncbi.nlm.nih.gov/40255502/
27. Archives of Women’s Mental Health. Prevalence and risk of anxiety and depression in PCOS. 2024. https://link.springer.com/article/10.1007/s00737-024-01526-1
28. Medical News Today. What to know about post-pill PMOS. 2026. https://www.medicalnewstoday.com/articles/post-pill-pcos
29. Illume Fertility. Fertility treatment costs (2026 update). https://www.illumefertility.com/fertility-blog/ultimate-guide-to-fertility-treatment-costs